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ABSTRACT 
An abstract of the thesis of Venkat Raghav Aachi for the Master of Science in Biology 
presented March 13,2009. 
Title: 	 Preliminary characterization of Mitochondrial ATP-sensitive potassium 
channel (MitoKA TP) activity in mouse heart mitochondria. 
Myocardial ischemia, infarction, heart failure and arrhythmias are the 
manifestations of coronary artery disease. Reduction of ischemic damage is a major 
concern of cardiovascular biology research. As per recent studies, the mitochondrial 
ATP-sensitive potassium channel (mitoKATP) opening is believed to playa key role in 
the physiology of cardioprotection, protection against ischemia-reperfusion injury or 
apoptosis. However, the structural information of mitoKATP is not precisely known. 
Elucidating the structural integrity and functioning of the mitoKATP is therefore a 
major goal of cardiovascular biology research. The known structure and function of 
the cell ATP-sensitive potassium channel (cellKATP) is functional in interpreting the 
structural and functional properties of mitoKATP. 
The primary goal ofmy research was to characterize the activity of mitoKATP in 
the isolated mitochondria from the control mouse heart. The mitoKATP activity, if 
preliminarily characterized in the control strains through the light scattering technique, 
then the structure of the channel could possibly be established and analyzed. by means 
of the transgenic model and with the help of immunological techniques such as 
western blotting and immunoflorescence. 
With this experimental model it was possible to demonstrate that the mitoKATP 
activity in control mouse heart mitochondria is activated by potassium channel 
openers (KeOs) such as diazoxide and cromakalim and activators ofmitoKATP such as 
PMA (phorbol12 myristate-l3-acetate), and inhibited by KATP inhibitors such as 
glibenc1amide and 5-hydroxydecanoate (5 HD). 
It was evident that the mitoKATP activity in mouse heart mitochondria was 
comparable to that exhibited by the rat heart mitochondria. The various selective and 
non-selective activators and inhibitors of the channel elicited their activity at a similar 
concentration used for the rat heart mitochondria. The results were reproducible in five 
independent experiments for each combination, further reinforcing the significance of 
existing channel activity in the mouse heart mitochondria. 
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CHAPTERl 
INTRODUCTION 
Cardiovascular disease can manifest as acute myocardial infarction, myocardial 
ischemia or arrhythmias [72, 75, 84]. Myocardial ischemia, as defined, is a reduction 
in the blood supply to the heart muscle owing to the constriction or obstruction of the 
coronary arteries. The lack ofblood supply to the heart leads to a reduction in the 
oxygen supply to the contractile heart muscle and eventual accumulation of toxic 
metabolites, leading to a permanent damage to the heart tissue. The irreversible 
necrosis of the heart tissue owing to the compromised blood supply manifests as 
infarction. The infarcted heart tissue loses the power to regenerate and subsequently 
ends up with a compromised ventricular function. [72, 75, 84] 
Reducing the morbidity and improving the clinical outcome in patients with coronary 
artery disease is a major concern of cardiovascular biology research. The 
mitochondrial ATP-sensitive potassium channel (mitoKATP) is thought to have a 
significant effect in the physiology of ischemic signaling pathway, protecting the 
myocardium against the ischemia-reperfusion injury (considering the reduction in the 
size of infarct when subjected to mitoKATP specific potassium channel openers during 
ischemic preconditioning; an effect reversed in the presence ofpotassium channel 
blockers) [46, 47]. It is therefore important to address questions regarding the 
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structural and functional properties ofmitoKATP to further delineate its role in health 
and disease. 
1.1 Rationale for mouse as the study model: 
Mice are probably the only mammalian species that are subjected to routine genetic 
manipulations. Also, the mouse genome is one of the most extensively studied 
genomes. The structural subunit assembly ofmitoKATP is quite unclear. It is still a 
matter of ambiguity what channel subunits constitute the mitoKATP. 
Through my study I intended to preliminarily characterize the mitoKATP activity in 
control mouse heart mitochondria. I believe that the mitoKATP activity if successfully 
characterized in the control mouse strains would eventually facilitate in understanding 
the structural constitution and assembly of the channel subunits through the study 
model of transgenic mice and various immunological techniques. Also, I intended to 
test the hypothesis that the mitoKATP activity exhibited in control mouse heart 
mitochondria is similar and comparable to that exhibited in rat heart mitochondria. 
The structure ofmitoKATP could be understood in much detail by pursuing the model 
ofgenetically modified mice (transgenic mice) with their cellKATP channel subunits 
over-expressed or knocked-out. Performing light scattering experiments on the 
isolated heart mitochondria from the transgenic mouse model, and by subjecting the 
isolated mitochondria to various selective and non selective KeOs and blockers, 
2 
would eventually facilitate in characterization of the mitoKATP activity in these study 
models. The structural subunits constituting the mitoKATP could be analyzed through 
various immunological techniques such as western blotting and immunoflorescence. 
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CHAPTER 2 
ATP- SENSITIVE POTASSIUM CHANNELS (KATP} 
There are two types of KATP channels constituting the cardiac myocyte. These include, 
the cellKATP channel / sarcolemmalKATP channel in the plasma membrane, and the 
mitochondrial KATP (mitoKATP) in the inner membrane of the mitochondria [1, 44, 77, 
82]. 
2.1 Plasma Membrane / Sarcolemmal KATP Channels (CellKATP) 
The potassium channels form the prime component of plasma membrane of cells of 
various tissues [1-6]. The potassium channels function in setting up a resting 
membrane potential, regulating the electrical activity and ion transport across the 
membrane. The ATP-sensitive potassium channels (KATP) were first identified in the 
plasma membrane of cardiac myocyte by Noma through his experiments using single 
channel patch clamp techniques [1]. CellKATpare expressed in diverse tissues of the 
body that include pancreatic ~ cells, skeletal muscle, smooth muscle and neurons of 
the brain parenchyma, in addition to the cardiac cells. [2,3,4,5,6] 
The cell ATP-sensitive potassium channels are involved in a variety of regulatory 
functions that include shortening of the action potential duration in cardiac myofibrils, 
loss of K+ ions during functional inhibition in heart, regulation of the skeletal muscle 
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excitation, pancreatic ~-cell release of insulin, relaxation of smooth muscle and the 
release of various neurotransmitters from the neurons of brain parenchyma [7, 8, 9]. 
2.2 Physiological roles of CellKATP 
The opening of the cellKATP leads to hyperpolarization of the cell plasma membrane. 
Hyperpolarization of the pancreatic ~-cells inhibits glucose-stimulated insulin 
secretion by preventing the increase in intracellular Ca+2. Depolarizing the plasma 
membrane of the pancreatic ~-cells leads to opening ofvoltage gated Ca+2 channels, 
elevation of intracellular Ca +2 and eventual exocytosis of insulin granules [10]. In the 
myocardium, excess efflux of K+ leads to a reduced influx of Ca+2 by decreasing the 
action potential duration. This reduced intracellular Ca+2 results in a reduction in the 
contractility of the heart and possible rhythm disturbances during ischemia [11, 12]. 
The cellKATP opening in the arteriolar smooth muscles results in a reduction in blood 
pressure, primarily mediated through a fall in the arteriolar resistance [13]. 
2.3 Pharmacological directive of cellKATP 
Intracellular ATP (ATPi) and ADP primarily regulate the activity of the cellKATP [4]. 
ATPi is functional in closing the channel and maintains the channel activity in the 
presence of Mg+2 [14-17]. Under normal physiological concentrations of A TPi, the 
probability of cellKATP to be in an open state is minimal. The ATPi is viewed to be 
bound to the cellKATP, for the channel to remain in the closed state. Hydrolysis ofATP 
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in the presence ofMg+2 emphasizes the pivotal role of protein phosphorylation in 
maintaining the channel activity [7]. 
The A TP inhibition of KATP channels is reversed by a class of drugs called potassium 
channel openers (KCOs) that include cromakalim, diazoxide, minoxidil, pinacidil and 
nicorandil. The properties ofKATP channels vary among tissues. For example pinacidil 
activates cardiac cellKATP but diazoxide does not; the pancreatic ~-cellKATP activity is 
weak in the presence ofpinacidil, but shows significant activity with diazoxide. Both 
diazoxide and pinacidil effectively activate smooth muscle cellKATP resulting in 
vasodilatation [7, 21, 22]. The differential activities exhibited by cellKATP lead to the 
assertion that there are receptor subtypes among cellKATP. [21,22] 
Glyburide and glibenclamide, which belong to the sulfonylurea class of anti-diabetic 
drugs, have also been found to block the activity of KATP. Inhibition of KATP channel in 
the pancreatic ~-cells leads to a series of events that eventually result in the release of 
insulin, and hence sometimes referred to as insulin secretagogues considering their 
pro-insulin action [3, 24, 25]. Their action on the cardiac and smooth muscle cells 
requires higher concentrations than in the pancreatic ~-cells [23]. Glyburide and 
glibenclamide are not really indicated in patients susceptible to ischemia, as they have 
been found to reverse the cardioprotective effects of the KCOs and result in rhythm 
disturbances [13, 19]. The inhibition ofKATP by ATP is independent of 
phosphorylation and the sensitivity of KATP channel to A TP is reduced in the presence 
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ofADP [70]. Glyburide and Glibenclamide are classified as non-specific KATP channel 
antagonists, considering their inhibitory action on the cellKATP and the mitoKATP. 
(Table1) 
2.4 Structure of cellKATP 
The complex of two different protein subunits namely, the inward-rectifying 
potassium channels (Kir) and the sulfonylurea receptor (SUR), form the cellKATP [28]. 
The Kir can exist either as Kir6.1 or Kir6.2 [18, 27] and the SUR can exist as SURl, 
SUR2A or SUR2B [29-31]. The regulatory SUR belongs to the ATP-binding cassette 
transporter family (ABC) [32,33, 72, 77]. The Kir subunit acts as a potassium 
conducting pore. The SUR subunit primarily regulates cellKATP activity [29, 30, 72, 
77]. 
The complementarity-determining DNA (cDNA) that encoded for Kir6.1 was initially 
isolated from the pancreatic islet cDNA library of the rat [25]. The composition of rat 
Kir6.1 primarily included two transmembrane domains with a 424-amino acid residue 
protein (Mr = 47,960). The Kir6.2 fragment was isolated by means of the Kir6.1 as the 
probe for screening the human genomic library [34]. The Kir6.1 was almost 70% 
identical to the Kir6.2 as revealed by the amino acid sequences [34,35]. The truncated 
form ofKir6.2 (with the last 26 or 36 amino acids deleted), when expressed in the 
absence of SUR, is found to be insensate to sulfonylureas, diazoxide, cromakalim and 
Mg-ADP [18, 36]. 
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SURI was recognized by means of radiolabeled analogs of glyburide. They were 
isolated in pancreatic ~-cells as a 140 kD protein on SDS-Polyacrylamide gel 
electrophoresis [26, 37]. Molecular cloning of SURI exposed that it encoded proteins 
of 1582 amino acids with 13 transmembrane domains and two nucleotide-binding 
folds (NBF) [31]. 
The cellKATP from the pancreatic ~-cells co-express SURI and Kir6.2 [34]. Mutations 
in NBF 1 and NBF2 are viewed as functional in the pathophysiology of familial 
hyperinsulinemic hypoglycemia of infancy [38, 39]. Walker A (W A) motifs ofNBFl 
and NBF2 are thought to be prospective sites ofMg-ADP activation of cellKATP [40]. 
The activation ofKATP channels by diazoxide required the W A motifs ofNBFl and not 
NBF2 [40]. 
The diverse isoforms of SUR, when co-expressed in various combinations with Kir 
subunits, demonstrates different sensitivities [29, 36]. For example the SUR2A / 
Kir6.2 complex regulates the activity of cellKATP in cardiac and skeletal muscle. This 
combination is more sensitive to pinacidil than to diazoxide [29]. The SUR2B / Kir6.2 
complex regulates the cellKATP activity of smooth muscle and is sensitive to both 
pinacidil and diazoxide [30]. Thus, the sensitivity of cellKATP to sulfonylureas, 
diazoxide and cromakalim requires the presence of SUR and the activation of the 
cellKATP by Mg-ADP also requires the presence of SUR [36]. 
8 
The verity that SUR1 contains two NBF whereas Kir6.2 has none, favors the 
assumption that inhibition of the channel by ATP requires binding ofATP to SUR 
[29,31]. The sensitivity of truncated Kir6.2 to ATP is enhanced by SUR1 as is evident 
from the shifting ofKi from approximately 100 IlM to 10 IlM [36]. 
As per recent studies it has been demonstrated that the Kir and the SUR subunits are 
associated with 1: 1 stoichiometry [41, 42, 43, 77]. The data also indicate that the 
channel pore of cellKATP is lined by four Kir subunits and four SUR regulatory 
subunits surrounding it, eventually functioning as a hetero-octameric structure [72, 
77]. 
The mitoKATP is thought to be qualitatively similar to the cellKATP, comprising the 
potassium conducting pore forming Kir subunit and the regulatory SUR subunit 
surrounding it. [51, 65, 90] [Fig 2] 
2.5 Mitochondrial KATP Channels (MitoKATP) 
Inoue et aI., in 1991, through their patch clamp studies on fused giant mitoplasts 
(mitochondria stripped of their outer membrane) from rat liver mitochondria, first 
reported the existence of A TP sensitive K+ channels in the hmer membrane of the 
mitochondria [44]. The principal properties ofmitoKATP include its improved 
sensitivity to K+ ions in comparison to Na+ and TEA +, high affinity inhibition with 
ATP and long chain acyl-CoA esters [44, 45], KCOs activation of the ATP inhibited 
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channels [46,47], and inhibition of the channel by glyburide, glibenclamide and 5­
hydroxydecanoate (5HD) [45,47,48]. All these physiological and pharmacological 
actions exhibited by mitoKATP are thus similar to cellKATP, although with a much lower 
conductance (10 pS in 100 mmol/L cytosolic K+ and 33 mmollL matrix Kl [44]. 
2.6 Regulation of matrix volume by MitoKATP 
The opening ofmitoKATP has been proposed to cause an increase in steady state 
matrix volume, respiratory stimulation (uncoupling), and alkalization of the 
mitochondrial matrix [72, 77]. The electrophoretic K+ uptake across the inner 
mitochondrial membrane is mediated through the process of diffusion and mitoKATP, 
as demonstrated by the mitochondrial potassium cycle [Fig. 1]. This influx of K+ under 
steady state is balanced by the electrophoretic H+ efflux through the electron transport 
chain. The mitochondrial matrix volume is determined by the net flux of K+ across the 
inner membrane along with the flux of anions like phosphate and osmotically 
regulated water [49, 70, 72, 77]. Opening of the mitoKATpleads to the influx ofK+ 
across the inner mitochondrial membrane and an eventual swelling of the 
mitochondrial matrix, with a minimal effect on the matrix K+ concentration. This net 
influx of K+ activates the electroneutral K+ / H+ antiporter that provide a compensatory 
K+ efflux so as to maintain a new steady state for a higher matrix volume [49-51]. The 
proton motive force derived from the electron transport chain provides the required 
energy to cause the movement of ions across the membrane. [Fig 1] 
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2.7 Oxidative phosphorylation 
The electrons carried by NADH and F ADH2 get combined with molecular oxygen 
through the electron transport chain. Peter Mitchell proposed the chemiosmotic 
hypothesis in order to understand the synthesis ofATP through the coupling of 
substrate oxidation [52]. The energy required to pump the H+ across the inner 
mitochondrial membrane from the matrix to the intermembrane space, is derived from 
the movement of electrons from the hydrogens on NADH and F ADH2, as they pass 
along the respiratory chain. The synthesis ofA TP by ATP synthase is mediated 
through the electrochemical gradient created by the movement of electrons. Oxidative 
phosphorylation is eventually concluded by the catalytic translation ofADP and Pi to 
ATP [52]. 
2.8 Myocardial Ischemia and cardioprotection 
Myocardial ischemia is a phenomenon of reduced blood supply to heart muscle due to 
the constriction or obstruction of the coronary arteries, resulting in an imbalance 
between the supply and demand for coronary arterial blood supply. As a result of this 
imbalance there is an accumulation ofpotentially toxic metabolites such as protons, 
carbon dioxide and lactic acid. Also there is a dearth of oxygen, substrates and energy 
in the tissues. The energy for myocardial contractility is derived from mitochondrial 
oxidative phosphorylation which subsequently influences the myosin ATPase activity. 
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The functions of the mitochondria are thus ofprime importance in the molecular 
events that lead to compromised myocardial function. [75] 
Subjecting the myocardiunl to repetitive alternating periods of ischemia followed by 
reperfusion, eventually followed by a prolonged ischemia-reperfusion, reflects 
ischemic-preconditioning (IPC) [75, 82]. Following ischemia, there is ATP depletion 
and subsequent reperfusion washes out the ischemic metabolites [53]. KCOs when 
used during ischemic preconditioning are cardioprotective, as evidenced by the size of 
the heart muscle infarct [20, 54, 75, 82]. This protective effect of KCOs is blocked by 
glyburide, glibenclamide and 5-hydroxydecanoate (5HD) [19, 20, 55, 75, 82]. 
KCOs through their action on the cardiac cellKATP are considered to cause a 
shortening of the action potential duration (APD) and hence protect the ischemic 
myocardium [56]. However, a lack of correlation between monophasic APD and 
cardioprotection by KCOs has resulted in contradicting this hypothesis, thus 
suggesting that the site of action of KCOs in cardiac muscle cells is discrete from 
cellKATP [57, 58]. This discrete site of action of cardioprotective effects ofvarious 
KCOs is believed to be the mitoKATP. [65, 72] 
2.9 MitoKATP as a receptor for KCOs and their inhibitors 
MitoKATP, a central intracellular pharmacological receptor is inhibited by A TP, and 
this inhibited mitoKATP is potentially activated by KCOs [46,47,48, 59, 60]. 
Cromakalim and Diazoxide, the prime activators ofmitoKATP, act in the low 
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micromolar range [46]. The distinct nature of the two cardiac KATP channels i.e., 
cellKATP and mitoKATP could probably be established through diazoxide which is more 
potent in activating the cardiac mitoKATP (K Y2, 0.4 JlmoIlL), roughly 2000 times more 
potent than for activating cardiac cellKATP (855 JlmollL) [46]. Glyburide, 
glibenclamide and 5HD, when studied in intact mitochondria, have been shown to act 
as inhibitors ofmitoKATP in the presence of ATP, Mg+2and a pharmacological opener 
such as diazoxide, cromakalim, or a physiological opener such as GTP [48]. 
Cardiac mitoKATP, but not cardiac cellKATP, is susceptible to the action of 5 HD and 
diazoxide and the cardioprotective effects of diazoxide are blocked by 5 HD [47]. It 
was eventually hypothesized by Garlid et al. that the phenomena of cardioprotection 
by KCOs in cardiac muscle cells was mediated through mitoKATP [47]. Liu et al. 
through their experiments on intact ventricular myocytes, showed that diazoxide was 
mitoKATP specific and not cellKATP specific [59]. Protein kinase C (PKC) mediated 
activation ofmitoKATP is a key element in the phenomenon of ischemic­
preconditioning (IPC), as emphasized by Sato et al. [60-64]. 
It was recommended by Inoue et al. [44] and Halestrap [83] that the regulatory sites of 
the mitoKATP nucleotides faced the mitochondrial matrix. Subsequently Garlid et al. 
through their studies on mitoKATP reconstituted into proteoliposomes and lipid bilayer 
membranes (BLM), concluded that the mitoKATP was unidirectional with respect to 
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nucleotide access and that the nucleotide binding sites ofmitoKATP faced the cytosol 
[70]. 
2.10 Sulfonylurea receptor of mitoKATP: 
Garlid et al. viewed that the mitoKATP comprised an inward-rectifying K+ channel 
(mitoKir) and a regulatory sulfonylurea receptor (mitoSUR), as was thought of in 
cellKATP [51, 65, 901 Paucek et al. through their studies using BODIPY-FL glyburide 
to photolabel inner mitochondrial membrane vesicles identified a protein that was 
precise and migrated at 63kD on SDS-Polyacrylamide gel electrophoresis [66, 67]. 
The fraction containing the 63kD protein (identified on partial purification on DEAE­
cellulose medium), when reconstituted in lipid vesicles, exhibited mitoKATP properties. 
It was henceforth hypothesized to be the regulatory sulfonylurea receptor ofmitoKATP 
[67]. 
Szewczyk et al. through photoaffinity labeling of sub-mitochondrial particles with 
[I125]-glibenclamide, recognized a 28kD inner mitochondrial membrane protein. This 
identified membrane protein demonstrated the activity of low-affinity sulfonylurea­
binding protein with an apparent Ko of 360 nM and BMAX of48 pmol per mg of inner 
membrane protein [68]. 
14 

2.11 Kir subunit of mitoKATP• 
Mironova et aI., on reconstituting an ATP-dependent K+ channel in the lipid bilayer 
using rat liver mitochondria, identified an activity with 55kD protein, that was 
inhibited with low affinity by ATP (K1I2 approximately 550 J.1M). They eventually 
suggested it to be the Kir subunit [69, 90]. MitoKATP activity was witnessed in 
liposomes that were reconstituted with partially purified fraction using rat liver and 
beef heart mitochondria by Paucek et al. [45]. The identified protein contained a major 
protein band at 54kD [45], with a saturating conductance of30 pS (1 mollL KCI). 
Further studies are awaited that can help identify and sequence the alleged Kir subunit 
of mitoKATP. 
The mitoKATP activity characterized in the control mouse model would eventually 
facilitate in understanding further the subunit assembly ofmitoKATP through the 
medium of genetically modified/transgenic mice and various immunological 
techniques. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Mitochondrial isolation: 
Inbred strain mice of type C57BL/6J from the Jackson lab were used for all the 
experiments. Three mice were used for each experiment in order to isolate significant 
amount ofmitochondrial protein. The mice were anesthetized with CO2 for one 
minute, incised through the abdomen, sternotomy performed and the hearts were 
excised. It was our observation that the time interval between the hearts excision and 
completion of homogenization influenced the channel activity (brief period of 2 
minutes); the lesser the time interval, the better the channel activity. The hearts were 
washed in ice cold Buffer A (250mM sucrose, 10mM HEPES, 5mM EGTA and pH 
7.2). The hearts were pounded with protease Imglml (type XXIV Sigma). The 
suspension was diluted up to two to threefold with buffer A supplemented with 0.5% 
bovine serum albumin (BSA). The suspension was then poured into a motorized 
Teflon pestle so as to get it homogenized. The homogenized suspension was then 
centrifuged in a Sorvall centrifuge for 3 minutes at 1500 g. The supernatant obtained 
was then centrifuged at 9000 g for 5 minutes. The consequential pellet was 
resuspended in Buffer A without BSA and centrifuged for 3 minutes at 2300 g. The 
ensuing supernatant was centrifuged for 5 minutes at 9000 g. The resulting final pellet 
was resuspended in Buffer A without BSA so as to have the final concentration as 35­
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40 mg/ml protein and was placed on ice. This technique of mitochondrial isolation is 
in agreement with that described by Jaburek et al. [48, 72, 77, 84] (Appendix A). The 
mitochondrial protein concentration was projected by means of the Biuret reaction 
[71]. Mitochondrial protein was assayed within two hours of isolation. The isolated 
mitochondria were placed on ice and were continuously stirred with the help of a 
magnetic stirrer to ensure free oxygen access during the experiments. This practice is 
in agreement with the American Physiological Society's "Guiding principles in the 
Care and Use of Animals", and was permitted by the Institutional Animal Care and 
Use Committee (IACUC) at Portland State University, Oregon. [72, 77, 84] 
3.2 Assay Medium: 
The mitochondria were suspended in an assay medium consisting ofpotassium 
chloride (KCI) (120mM); EGTA (O.lmM) (chelator of calcium ions); succinate 
(lOmM) (provides electrons to electron transport system); phosphoric acid (5mM); 0.5 
mM MgCh and pH 7.2. The osmolality range of the assay medium, as measured by 
the osmometer, was between 275-280 mosmollkg H20. All the runs were 
supplemented with 5 flM Rotenone and 0.67 flM Oligomycin. The experiments were 
performed at 30.5 °c [72, 77,84]. 
Rotenone is functional in inhibiting the reverse electron transfer from complex II to 
complex I of the electron transport chain. Oligomycin inhibits FoFt-ATP synthase of 
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the electron transport chain. The synthesis ofATP is henceforth interrupted and the 
membrane potential is subsequently decreased. [72, 77, 84] 
The volume of the assay medium used for experiments involving rat heart 
mitochondria was 3 ml in my lab. I tried to reduce the volume and work with the 1.5 
ml assay medium in order to perfonn significant number of light scattering runs to 
validate the mitoKATP activity. 
3.3 Measurement of mitochondrial volume: 
K+ uptake is assayed following the mitochondrial matrix swelling. The light scattering 
technique is functional in measuring the changes in mitochondrial volume that escort 
the net salt transport into the mitochondria. The light scattering technique is based on 
the principle that the reciprocal absorbance (A-I) at 520 nm and 0.1 mg/mlofthe 
mitochondrial suspension at 30.5 °c, is linearly related to matrix volume, as described 
by Beavis et al. [71, 72]. ~ is a dimensionless factor that nonnalizes A-I (inverse 
absorbance) for mitochondrial protein concentration, P (mg/ml) 
a is a machine constant (0.25 for our apparatus) and Ps equals 1 mg/ml. [72, 77, 84] 
An increase in matrix volume, owing to the osmotic swelling ofmitochondria (due to 
uptake of salts and water), is accompanied by a decrease in light intensity. The light 
scattering technique measures this change in matrix volume of the mitochondria. The 
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light scattering technique is primarily functional in investigating the mitoKATP activity 
in intact isolated mitochondria. The light scattering technique is beneficial in 
comparison to the reconstitution studies, considering that the mitochondrial ion 
channels and the bioenergetic apparatus are intact and also the various regulatory 
agents could possibly be applied directly to the mitochondria. Limitations include the 
unphysiological ion gradient's usage, substrate or nucleotide concentrations, and a 
possible influence ofneighboring organelle membranes [48]. The data measured by a 
Brinkmann PC 700 light probe is converted to digital information (A-1) using a "Lab 
view" program designed exclusively for use in our laboratory. [72, 84] 
Diazoxide, and other hydrophobic compounds soluble in dimethyl sulfoxide (DMSO), 
are always added 2-3 seconds after the mitochondrial suspension to guarantee equal 
distribution. Also, diazoxide is not effective in the absence of ATP, since it cannot 
activate a channel that is previously in its open state. Similarly, 5 hydroxydecanoate (5 
HD), a specific mitoKATP antagonist is ineffective in the absence of ATP and the KCO 
diazoxide. This is because 5 HD prevents the diazoxide mediated mitoKATP activation, 
but by itself does not inhibit the channel activity. The same observations hold good for 
cromakalim, PMA and glibenclamide as well. Light scattering traces were initiated on 
adding the mitochondrial suspension with the first 5-7 seconds omitted for precision. 
The channel activity was followed over a period of 180 seconds. [72, 77, 84] 
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The final concentration of the stock mitochondria added to the assay medium was 0.1 
mg protein/ml. The volume of the assay medium was 1.5 ml for each run. Data 
analysis followed each individual experiment. Rate of swelling was determined by the 
slope of the traces on addition of the various KCOs, activators of mitoKATP and their 
blockers. The analysis program used was "ORIGIN", a data-analysis program by 
Microcal (Northampton, MA, USA). [72, 84] 
Statistical analysis: Data are presented as mean +/- SD. Data were analyzed using 
unpaired Student's t-test of the means using Microcal Origin software (Northampton, 
MA). A value of P < 0.05 is considered statistically significant. 
3.4 Chemicals 
All the chemicals used for the experiments were from Sigma Chemical Co. (St. Louis, 
MO, USA). Mice were ordered from the Jackson laboratory (Maine, USA). 
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CHAPTER 4 

KATP CHANNEL OPENERS AND BLOCKERS: 

One of the most credible means to establish and identify the functions of cardiac 
sarcolemmal and mitochondrial KATP channels is through the medium of KATP channel 
openers and blockers. The pharmacological agents could probably be classified as 
selective and non-selective based on their putative sites of action in heart, the former 
acting exclusively on the mitoKATP and the latter acting either on SarCKATP / mitoKATP 
as shown in Table 1 and represented structurally in figures 15 and 16. 
4.1 Non-selective KATP agonists: 
Cromakalim, synthesized in 1980 represents the archetype of the benzopyrans class of 
drugs. Used as a cardioprotective drug in experimental routines, it lacks specificity in 
its site of action (mitoKATP vs cellKATP). It functions in shortening the action potential 
duration (APD) and causes vasodilatation [80, 82]. 
Nicorandil, belongs to the pyridyl nitrate class of drugs and causes significant 
vasodilatation due to its NO (nitric oxide) donor properties. It has a non-specific site 
of action in the cardiac myocyte [80, 82]. 
P 1075 is a widely studied potent cyanoguanidine. It lacks selectivity versus the 
mitoKATP as was shown in ischemia-reperfusion studies on rat and rabbit cardiac 
myocytes [82]. 
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4.2 Selective mitoKATP agonists: 
Diazoxide, a benzothiazidine class of drug is a selective mitoKATP agonist under 
normal conditions. It also causes activation of smooth muscle KATP and endothelial 
KATP isoforms. Diazoxide is probably the only KATP opener that binds equivocally to 
SUR 1 and SUR 2B subunits. It is routinely used in low doses to establish the 
importance ofmitoKATP in preconditioning. A long term use ofdiazoxide is related to 
the development of hyperglycemic state owing to its role in insulin inhibition [46, 82]. 
BMS-191095 «3R)-trans- 4-« 4-chlorophenyl)-N-( 1H-imidazol-2-ylmethyl)dimethyl­
2H-l-benzopyran-6-carbonitril monohydrochloride) belongs to the benzopyrans class 
of drugs with a higher cardiac selectivity and anti-ischemic potency. It was shown to 
improve the post- ischemic cardiac function and a reduction in the LDH (lactate 
dehydrogenase) release. Grover et a!. through their studies using reconstituted 
mitoKATP observed that BMS 191095 activated the mitoKATP and the activation was 
inhibited by both 5 HD and glibenclamide [79, 82]. 
4.3 KATP channel blockers: 
5 HD (5 hydroxydecanoate), regarded as a specific inhibitor ofmitoKATP, is used in 
most studies to assess the activity of the mitoKATP channel. It has been observed that 
the diazoxide activated mitoKATP influx of K+ ions is reversed in the presence of 5 HD 
in isolated rat heart mitochondria [48]. 
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Glibenclamide, an anti-diabetic drug belonging to the sulfonylurea class, is 
implemental in blocking the activity of the KATP channel. It shows marked variability 
in its actions with different affinity grades, exhibiting SUR1 blocking properties 
involving pancreatic KATP and the SUR2A12B subunits expressed on the cardiac and 
the vascular cells [80, 82]. 
HMR 1098 belongs to the sulfonylthiourea class and is considered as a selective 
cellKATP blocker. It is generally used along with a non-specific KATP blocker to 
examine the physiology of IPC [81]. 
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CHAPTER 5 
RESULTS: 
The effects of ATP, KCOs (diazoxide, cromakalim), mitoKATpactivators (such as 
PMA) and inhibitors (5 HD and glibenclamide) on mitochondrial matrix swelling 
are potassium-specific. 
The mitochondrial potassium cycle is an important constituent in maintaining the 
mitochondrial volume homeostasis [Fig 1]. The swelling of the mitochondrial matrix 
is witnessed as an increase in light scattering and is proportional to the net salt influx 
[72, 77, 84]. The light scattering technique is functional in investigating the mitoKATP 
activity in intact isolated mitochondria. The typical light scattering traces from control 
mouse heart mitochondria in a respiring K+ rich medium are shown in figures 4 - 9. 
Figure 4 demonstrates light scattering traces from mouse heart mitochondria respiring 
in succinate supplemented K+ medium at 30.5 °C. The light scattering parameter ~, an 
index of matrix volume, is plotted against time. In the absence ofATP (open/control), 
the mitochondrial matrix attained a higher steady state volume. On addition of 200 JlM 
ATP there is an apparent lower rate of swelling and ultimately a lower steady state 
volume (ATP). The ATP inhibition of the channel was reversed by 30 JlM diazoxide 
(ATP + DZX), and the opening effect ofdiazoxide was blocked by 300 JlM 5 HD 
(ATP + DZX + 5 HD). [Fig. 4] 
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Figure 5 demonstrates light scattering traces from mouse heart mitochondria respiring 
in the same succinate supplemented K+ medium at 30.5 °C. In the absence of ATP, the 
mitochondrial matrix scaled to a higher steady state volume. Addition of 200 )lM ATP 
lowered the rate of swelling. The inhibition of the channel by ATP was reversed by 30 
)lM diazoxide, and the activator effect of diazoxide was inhibited by 10 )lM 
glibenclamide. [Fig. 5] 
Figures 6 and 7 demonstrate light scattering traces initiated from mouse heart 
mitochondria respiring in the same K+ medium supplemented with succinate. It was 
evident that the mitochondria had swollen to a new steady state volume in the absence 
ofATP (open) and the addition of 200 )lM ATP lowered the swelling. The channel 
was re-activated by cromakalim (50 )lM) and this activator effect was inhibited by 
both 5 HD (300 )lM) and glibenc1amide (10 )lM). [Fig. 6 & 7] 
Figures 8 and 9 illustrate the light scattering traces demonstrated by isolated mouse 
heart mitochondria respiring on succinate supplemented K+ medium. The 
mitochondria, owing to the matrix swelling, attained a new steady state volume in the 
absence of ATP (open! control trace), an effect inhibited ill the presence of 200 )lM 
ATP. On addition of a PKC€ activator PMA (0.2 )lM), the mitoKATP got reactivated 
and almost superimposed on the open trace. But this activated mitoKATP was inhibited 
by both 5 HD (300 )lM) and glibenc1amide (10 )lM). [Fig. 8 & 9] 
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Figures 10, 11 and 12 graphically illustrate the summary of the percentage mitoKATP 
activity exhibited by isolated mouse heart mitochondria in the presence of activators 
diazoxide, cromakalim, PMA, and inhibitors 5 HD, glibenclamide. The data establish 
the capacity ofATP to inhibit the channel, the openable effects of various KCOs and 
the inhibitory actions of K+ channel blockers. P value was less than 0.05 and hence 
statistically significant. The data also validates the monitoring capacity of the assay 
medium. The results summarized represent five independent experiments for each 
combination. Data are presented as mean +/- SD. Data were analyzed using unpaired 
Student's t-test of the means using Microcal Origin software. P < 0.05 is considered 
statistically significant. 
Figure 13 represents typical light scattering traces from rat heart mitochondria 
respiring in succinate supplemented K+ medium (120mM) at 30.5 °c. It can be noted 
that the mitochondrial matrix had swollen to a higher steady state in the absence of 
ATP (open/control). When 200 J-lM ATP was added it resulted in a lower steady state 
volume. ATP inhibition was overcome by 30 J-lM diazoxide and the diazoxide 
activated channel was inhibited by 300 J-lM 5 HD [Fig. 13]. The light scattering traces 
look similar to those in the mouse heart mitochondria. The results obtained with the 
combination of diazoxide and 5 HD were reproducible by combining diazoxide + 
glibenc1amide (10 J-lM), cromakalim (50 J-lM) + 5 HD or cromakalim + glibenclamide, 
and also PMA (0.2 J-lM) + 5 HD or PMA + glibenc1amide. (data not shown) 
26 
Figure 14 demonstrates bar graphs representing the comparison between percentage 
mitoKATP activity exhibited by rat and mouse heart mitochondria under the same 
experimental conditions. Rates in the absence of A TP were set as 100% and in the 
presence of A TP as 0%. The effects of various KCOs and blockers are assessed in 
relation to the set controls. It can be seen that the percentage mitoKATP activity 
exhibited by mouse heart mitochondria is comparable to that exhibited by rat heart 
mitochondria when subjected to various potassium channel openers and their blockers. 
Data are presented as mean +/- SO. Data were analyzed using unpaired Student's t-test 
of the means using Microcal Origin software. 
5.1 Mechanism of activation of mitoKATP by PMA: 
PMA is a protein kinase C epsilon (PKCe) activator which eventually activates the 
mitoKATP. The activation of PKCe phosphorylates the mitoKATP and ultimately opens 
it. PKCe has been shown to be bound to the inner membrane of the mitochondria and 
associated in a functional complex with mitoKATP. This was demonstrated using the 
techniques of detergent extraction and chromatographic isolation of mitochondrial 
membrane proteins. The PKCe activated mitoKATP results in an influx ofpotassium, 
an effect negated in the presence ofphosphatases. The K+ influx causes the matrix 
alkalinization, retarding the reduction ofQ to QH2 at Complex 1 of the electron 
transport chain and eventually resulting in the H20 2 production by reducing the 
molecular oxygen. MitoKATP activated K+ influx and eventual ROS (reactive oxygen 
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species) production is mediated through the KCOs and also mitoKATP associated 
PKCB activation [75, 78]. [Fig 3] 
When used in the 0.2 JlM concentration, the PKCB mediated activation of mitoKATP by 
PMA was inhibited by both 5HD and glibenc1amide. [Fig 8,9, 12] 
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Table 1: 
Pharmacological agents currently under investigation to validate the KATP 
channel activity: 
Pharmacological agent Putative site of action in 
heart 
Agonist! Antagonist 
Cromakalim CellKATplMitoKATP Agonist 
Nicorandil CellKATPlMitoKATP Agonist 
Diazoxide MitoKATP AgonistI 
P-I075 CellKATP/MitoKATP Agonist 
BMS191095 MitoKATP Agonist 
5-hydroxydecanoate MitoKATP Antagonist 
Glybriride/Glibenclamide MitoKATP ICellKATP Antagonist 
HMR-I098 CellKATP Antagonist 
TPP MitoKATP ICellKATP Antagonist 
Table 1 demonstrates the various pharmacological agents currently under investigation 
worldwide to assess the ATP-sensitive potassium channel (KATP) activity along with 
their putative sites of action in heart and their mode of action (agonist vs. antagonist). 
Cromakalim, Nicorandil and P-I075 are considered as non-selective agonists ofKATP 
since they are believed to act on the cellKATP and the mitoKATP. Diazoxide and 
BMS191095 are considered tobe mitoKATP specific agonists. 5-hydroxydecanoate 
(5H;D) is a mitoKATP specific antagonist and HMR-l 098 is a cellKATP specific 
antagonist. Glyburide, Glibenclamide and TPP are non-selective KATP channel 
antagonists. 
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Mitochondrial Potassium Cycle 
H+ H+ H+ 
Electron Transport 
System 
Intermembrane Space 
K+ 
K+ K+ H+ 
MitochondrialMatrix 
H+ 
K+ 
lea~ 
K+ 
Fig 1: Mitochondrial Potassium cycle. The proton motive force that is generated by 
the electron transport system creates a membrane potential that drives K+ influx via 
diffusion (K+ leak) and mitoKATP (located on the inner membrane). The electroneutral 
Pi/OH exchanger drives phosphate inside so that the net K+ influx is accompanied by 
anions and osmotically obligated water. The electroneutral K+/ H+ antiporter regulated 
on the matrix side by volume changes, Mg+2 and H+, provides an efflux ofexcess K+ 
accompanied by Pi and water, thereby preventing excessive matrix swelling. [49, 50, 
51, 77] 
30 

Proposed interaction of regulatory ligands with mitoKATP 
Mitochondrial 
DEB 
Cromakalim 
P1075 
BMS191095? 
Nicorandil? 
ATP+ Mg+2 
Glibenclamide 
5-HD Diazoxide GTP UDB 
matrix 
IMS 
Fig 2: A proposed illustration of the mitoKATP channel subunits with the possible 
interaction sites of the regulatory ligands (illustration modified from reference 
[90]). MitoKATP is thought to be represented by four 55-kDa Kir subunits and four 63­
kDa SUR subunits, functioning as a hetero-octamer. MitoKir is viewed as a 
conduction pore of the channel and is surrounded by the regulatory SUR subunits that 
contain one or more nucleotide binding folds (NBF). The Kir subunits regulate the 
movement ofK+ across the membrane. The Kir subunits are thought to mediate the 
inhibitory effects ofATP (in the absence ofMg+2) and TPP+, and activation effects of 
UDP and DEB. The SUR subunits, belonging to the ABC family, demonstrate the 
sites ofpossible inhibition by ATP + Mg+2, Glibenclamide and 5-HD. The activation 
of the channel by diazoxide, GTP, cromakalim, PI075 and possibly BMS191095 and 
nicorandil, is thought to be mediated through the SUR subunits. [90] 
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Intramitochondrial signalling pathway" PMA mode of action 
Cardioprotection 
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1M 
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Fig 3: Intramitochondrial signalling pathway triggered by cGMP activated 
mitoKATP (illustration modified from reference [78]).PKG delivers the signals to 
the mitochondria that arise from the Gi- coupled receptors. The signal is transmitted to 
PKC€ 1 located on the inner mitochondrial membrane (IM) from PKG phosphorylation 
of an unknown mitochondrial outer membrane (OM) protein. Activated PKC€l causes 
phosphorylation and opening of the mitoKATP. MitoKATP opening via PKC€ 1 activation 
by PMA or by KATP channel openers such as diazoxide or cromakalim results in K+ 
influx, increase in matrix pH and increased H20 2 (reactive oxygen species) 
production. The H20 2 produced inturn activates PKC€ 1 and PKC€2. The activated 
PKC€2 inhibits the mitochondrial permeability transition (MPT) which eventually 
decreases cell necrosis, infarct size and inhibits apoptosis. [75, 78, 82] 
Abbreviations used: cGMP, cyclic Guanosine monophosphate; PKG, protein kinase 
G; PM A, PhorboI12-myristate-13-acetate; OM, outer membrane; 1M, inner 
membrane; IMS, inter membranous space; PKC €, protein kinase C epsilon; H20 2, 
hydrogen peroxide; MPT, mitochondrial permeability transition; mkATP, 
mitochondrial KATP; "+" sign indicates activation; "-" sign indicates inhibition 
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Light scattering traces illustrating mitoKATP activity in mouse heart 
mitochondria: 
5HD inhibits diazoxide activated nitoKATP0.330 
c 
0 60 120 180 240 
Time (sees) 
0.315 
J3 0.300 
0.285 
a 
d 
b 
a ...CPEN 
b....+AlP 
c....+A1P+DZX 
d....+A1P+DZX+5H) 
0.270 
Fig 4: 5-hydroxydecanoate (5 HD) inhibits the pharmacological opening of 
mitoKATP by diazoxide. Light scattering traces from mouse heart mitochondria 
respiring on succinate in IC medium (120 mM) at 30.5 °C. The light scattering 
parameter p, an index of matrix volume, is plotted against time. 
Trace a: K+ influx in the absence ofATP (open/control) 
Trace b: K+ influx in the presence of 0.2 mM ATP 
Trace c: Reversal ofA TP inhibition by 30 JlM Diazoxide (the trace almost 
superimposes on the open trace) 
Trace d: Reinhibition by 300 JlM 5-hydroxydecanoate in the presence of30 JlM 
diazoxide and 0.2 mM ATP (the trace almost superimposes on trace 'b') 
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Glibenclaride inhibits dazoxide activated nit~TP 
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240 
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Fig 5: Glibenclamide inhibits the pharmacological opening of mitoKATP by 
diazoxide. Light scattering traces of mouse heart mitochondria respiring on 
succinate rich IC medium (120 mM) at 30.5 °c. The light scattering parameter p, 
an index of matrix volume, is plotted against time. 
Trace a: Resting mitoKATP channel in open state (control) 
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) 
Trace c: Activation ofmitoKATP by diazoxide (30 J.1M) in the presence ofATP (0.2 
mM) (the trace almost superimposes on the open trace) 
Trace d: Inhibition of diazoxide activated mitoKATP by glibenclamide (l0 J.1M) in the 
presence of ATP (the trace almost superimposes on trace 'h') 
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5HD inhibits cromakaIim activated nitoKAlP 
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Fig 6: 5-hydroxydecanoate (5 HD) inhibits cromakalim (CRM) activated 
mitoKATP. Light scattering traces showing the activity of mitoKATP in mouse heart 
mitochondria respiring on succinate supplemented IC medium (120 mM) at 30.5 
°C. The light scattering parameter p, an index of matrix volume, is plotted 
against time. 
Trace a: Resting mitoKATP channel in open state (control) 
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) 
Trace c: Activation ofmitoKATP by cromakalim (50 JlM) in the presence ofATP (0.2 
mM) (the trace almost superimposes on control trace) 
Trace d: Inhibition of cromakalim activated mitoKATP by 5HD (300 JlM) in the 
presence of ATP (the trace almost superimposes on trace 'b') 
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Glibenclanide inhibits CromakaIim activated nit~1P 
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Fig 7: Glibenclamide inhibits the cromakalim activated mitoKATP.Light 
scattering traces showing the activity of mitoKATP in mouse heart mitochondria 
respiring on succinate supplemented IC medium (120 mM) at 30.5 °C. The light 
scattering parameter p, an index of matrix volume, is plotted against time. 
Trace a: Resting mitoKATP channel in open state (control) 
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) 
Trace c: Activation ofmitoKATP by cromakalim (50 JlM) in the presence ofATP (0.2 
mM) (trace almost superimposing on trace 'a') 
Trace d: Inhibition of cromakalim activated mitoKATP by glibenclamide (10 JlM) in 
the presence ofA TP (the trace almost superimposes on trace 'b') 
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Fig 8: Glibenclainide inhibits the PMA activated mitoKATP. Light scattering 
traces showing the activity of mitoKATP in mouse heart mitochondria respiring on 
succinate supplemented K+ medium (120 mM) at 30.5 °C. The light scattering 
parameter p, an index of matrix volume, is plotted against time. 
Trace a: Resting mitoKATP channel in open state (control) 
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) 
Trace c: Activation of mitoKATP by PMA (0.2 J.1M) in the presence of ATP (0.2 mM) 
(trace almost superimposing on trace 'a') 
Trace d: Inhibition of PMA activated mitoKATP by glibenclamide (10 J.1M) in the 
presence of ATP (the trace almost superimposes on trace 'b') 
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5HD inhibits PMAactivated nit~1P 
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Fig 9: 5 HD inhibits PMA activated mitoKATP. Light scattering traces showing the 
activity of mitoKATP in mouse heart mitochondria respiring on succinate 
supplemented ~ medium (120 mM) at 30.5 °C. The light scattering parameter p, 
an index of matrix volume, is plotted against time. 
Trace a: Resting mitoKATP channel in open state 
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) 
Trace c: Activation ofmitoKATP by PMA (0.2 JlM) in the presence ofATP (0.2 nlM) 
(trace seen almost superimposing trace 'a') 
Trace d: Inhibition ofPMA activated mitoKATP by 5 HD (300 JlM) in the presence of 
ATP (the trace almost superimposes on trace 'b') 
38 
100 N=5 
~ 80 
:~ 
~ 60 
~ ~ 40 
S 
?J!. 20 
0 
-ATP +ATP 
Fig 10: Summarized data for the percentage mitoKATP activity exhibited by 
isolated mouse heart mitochondria when subjected to KCO diazoxide and 
blockers 5 hydroxydecanoate (5 HD) and glibenclamide. The results summarized 
are for five independent experiments for each combination. Error bars represent 
SDs from the average of five individual experiments. 
Open: Control traces with no ATP (100% mitoKATP activity) 
ATP: % mitoKATP activity in the presence of 0.2 mM ATP (0%) 
DZX: % mitoKATP activity in the presence of 30 JlM diazoxide + 0.2 mM ATP 
DZX+5-HD: % mitoKATP activity with 30 JlM DZX+ 300 JlM 5-HD+ 0.2 mM ATP 
DZX +GLI: % mitoKATP activity with 30 JlM DZX + 10JlM glibenclamide + 0.2 mM 
ATP 
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Fig 11: Summarizing the % mitoKATP activity exhibited by isolated mouse heart 
mitochondria when subjected to cromakalim alone and in combination with 5­
HD and glibenclamide. The results summarized are for N=5 for each 
combination. Error bars represent SDs from the average of five individual 
experiments. 
Open: Control traces with no ATP (100% mitoKATP activity) 
ATP: % mitoKATP activity in the presence of 0.2 mM ATP (0%) 
CROM: % mitoKATP activity in the presence of 50 flM cromakalim + 0.2 mM ATP 
CROM+5-HD: % mitoKATP activity with 50 flM cromakalim+ 300 flM 5-HD+ 0.2 
mMATP 
CROM+GLI: % mitoKATP activity with 50 flM cromakalim+ lOflM glibenc1amide + 
0.2mMATP 
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Fig 12: Summarizing the % mitoKATP activity exhibited by isolated mouse heart . 
mitochondria when subjected to PMA alone and in combination with 5-HD and 
glibenclamide. The results summarized are for N=5 for each combination. Error 
bars represent SDs from the average of five individual experiments. 
Open: Control traces with no ATP (100% mitoKATP activity) 
ATP: % mitoKATP activity in the presence of 0.2 mM ATP (0%) 
PMA: % mitoKATP activity in the presence of 0.2 JlM PMA + 0.2 mM ATP 
PMA+5-HD: % mitoKATP activity with 0.2 JlM PMA+ 300 JlM 5-HD+ 0.2 mM ATP 
PMA+GLI: % mitoKATP activity with 0.2 JlM PMA+ 10JlM glibenc1amide + 0.2 mM 
ATP 
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Fig 13: A typical light scattering trace showing the activity of mitoKATP in rat 
heart mitochondria under the same experimental conditions i.e., respiring on 
succinate supplemented K+ medium (120 mM) at 30.5 °C. The light scattering 
parameter p, an index of matrix volume, is plotted against time. 
Trace a: Resting mitoKATP channel in open state (controVopen) 
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) (+ ATP) 
Trace c: Activation of mitoKATP by Keo diazoxide (30 JlM) in the presence of ATP 
Trace d: Inhibition of activated mitoKATP by 5 HD (300 JlM) in the presence of ATP 
and diazoxide 
Note: The results obtained with the combination of diazoxide and 5 HD were 
reproducible by combining diazoxide + glibenc1amide (10 JlM), cromakalim (50 JlM) 
+ 5 HD or cromakalim + glibenclamide, and also PMA (0.2 JlM) + 5 HD or PMA + 
glibenc1amide. (data not shown) 
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Fig 14: The following figure compares the % mitoKATP activity activity exhibited by 
both rat and mouse heart mitochondria under the same experimental conditions and in 
the presence ofvarious potassium channel openers and blockers. Error bars represent 
SDs from the average of five individual experiments. The rates in the absence of A TP 
(open) were set as 100% and in the presence of A TP as 0%. The various openers and 
blockers are analyzed in relation to these set controls. 
• 	 Diazoxide (DZX) has caused a significant reactivation of the mitoKATP in both 
rat and mouse heart mitochondria. This effect is significantly inhibited by 5HD 
in both study models. 
• 	 The openable effects of cromakalim (CRM) on mitoKATP are significantly 
inhibited by 5HD in both rat and mouse heart mitochondria. 
• 	 The activation ofmitoKATP by PMA is significantly inhibited in the presence 
of 5HD in both the study models. 
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Fig 15: Chemical structures of KATP channel activators 
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Fig 16: Chern· Ical structures of KATP blockers 
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CHAPTER 6 
DISCUSSION: 
Mitochondrial ATP sensitive potassium channels (mitoKATP) are believed to be 
integral in the physiology of cardioprotection and cardiac ischemia related 
manifestations [46, 47, 72, 77]. The various cardioprotective drugs such as diazoxide 
are thought to act through the mitoKATP and hence involved in cardioprotection, as 
evidenced by the infarct size post ischemic-preconditioning and ischemia-reperfusion 
injury [46, 47, 51, 75, 78, 82]. 
ATP-sensitive potassium channels (KATP) are found in a variety of tissues that include 
pancreatic ~-cells, neurons ofbrain parenchyma, heart, skeletal and smooth muscle 
cells [1]. Cardiac cells contain two divergent KATP channels, the classical one in the 
sarcolemma (cellKATP) [1] and the other in the inner membrane of the mitochondria 
(mitoKATP) [44, 73]. Garlid et aL observed that the mitoKATP exhibited several 
properties comparable to those of the cellKATP. [45,69, 77, 90] 
CellKATP are implicated in a variety of roles and are implemental in transitioning the 
metabolic status of a cell into a physiological effect [21, 86, 87, 88, 89]. Kir and SUR 
subunits, that are heteromultimers, constitute the cellKATP [29,31,69, 90]. Kir is 
believed to assemble with SUR as a 4:4 complex and function as an octameric channel 
[29,31,41,42,69,90]. The SURs are members of the ATP-binding cassette (ABC) 
family [29, 31, 69, 77]. The genes that encode SURI and SUR2 are mostly 
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homologous, while SUR2A (cardiac) and 2B (smooth muscle) are splice variants [29, 
77, 90]. SURI is thought to regulate the pancreatic ~ channel activity, SUR2A the 
cardiac channel, and SUR 2B the smooth muscle channel [29, 30, 31, 77]. Kir 
channels are tetramers and have two transmembrane domains linked by a pore loop. 
[29, 30, 31, 37, 77] 
The subunits that configure the mitoKATP are thought to be qualitatively equivalent to 
the cellKATP [77, 90]. The activity ofmitoKATP is modulated by various biochemical 
and pharmacological agents, some reacting with mitoSUR (mitochondrial sulfonylurea 
receptor), and others with mitoKir (mitochondrial inward rectifying potassium channel 
receptor) [Fig 2] [77, 78, 90]. Garlid et al. showed that mitoKATP is a high affinity 
receptor for K+ channel openers (KCOs), including cromakalim, diazoxide and PMA 
(a PKCB activator), and this activation is inhibited in the presence of 5 HD and 
glibenclamide. [46,47,48, 72, 75, 90] 
Through my experiments I have tried to characterize the activity ofmitoKATP in the 
mitochondria of control mouse by testing the activity of this channel in the presence of 
various specific and non-specific potassium channel openers and their blockers. It was 
evident from my results that the cpannel was significantly active in the mouse heart 
mitochondria. The light scattering traces initiated in the presence of various KCOs and 
their inhibitors showed results that were comparable to those in the rat heart 
mitochondria [Fig 13 & 14]. The various selective and non-selective activators and 
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inhibitors of the channel exhibited their activity at a concentration that was identical to 
that used for the rat heart mitochondria. Diazoxide, a selective KCO activated the 
channel in 30 J.lM range, a concentration at which a significant channel activity was 
witnessed in rat heart. This activator effect of diazoxide was inhibited by 5 HD (300 
J.lM) and glibenc1amide (10 J.lM). Cromakalim, a non-selective KCO demonstrated 
significant channel opening when added as a 50 J.lM final concentration. The channel 
activity was inhibited by both 5 HD and glibenc1amide. PhorboI12-myristate-13­
acetate (PMA), which is a PKC6 (Protein Kinase C epsilon) activator, caused a 
significant activation of the mitoKATP in the 0.2 J.lM range; an effect that was inhibited 
by 5-hydroxydecanoate (5 HD). Channel activity was evident considering and 
comparing the rates of various light scattering traces initiated. 
The mitoKATP activity, having been characterized in control mouse heart 
mitochondria, would eventually be an ideal platform to explore further the structural 
components of the mitoKATP. The model of transgenic mouse/genetically modified 
mouse, powered with the light scattering technique and immunological tools such as 
western blots and immunoflorescence techniques, would be one of the most ideal and 
logistic extensions in identifying and establishing the subunit assembly of the 
mitoKATP• Also, from the data analysis it seems evident that the mitoKATP activity 
exhibited by control mouse heart mitochondria is similar and comparable to that 
exhibited by the rat heart mitochondria considering the channel activity exhibited in 
the presence ofvarious potassium channel openers and their blockers. The data 
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validates the use of the mouse as a comprehensive study model for the analysis of 
mitoKATP activity in the heart mitochondria. 
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APPENDIX A: Mouse heart mitochondria isolation protocol 
Solutions 
Buffer A BufferB 
Sucrose 
HEPESpH7.2 
EGTA 
250mM 
10mM 
5mM 
Sucrose 
HEPESpH 7.2 
EGTA 
250mM 
10mM 
5mM 
BSA 5 mglmL [i.e. Buffer A without BSA] 
Procedure 
1. Anesthetize 2-3 mice with carbon dioxide (--30 sec) 
2. Quickly remove heart(s) and place in a 20 mL beaker, on ice, filled with ice-cold 
BufferB. 
3. Using a squeezing action, manually remove as much blood as possible. Decant off 
the bloody buffer. (--15 sec) 
4. Add 10-15 mL of Buffer B supplemented with 1mglmL protease (Nagarse ­
protease Sigma Type XXIV) and cut into very small pieces with a sharp scissor. (30­
60 sec) 
5. Pour the diced suspension into a 50 mL, ice-jacketed Potter-Elvegen tissue grinder 
with Teflon pestle, add 30-40 mL ice-cold Buffer A and homogenize at moderate 
speed (75% of max). Usually 5-6 strokes are enough for a good homogenization. 
NOTE: Additional strokes will not necessarily increase protein yield, but certainly will 
increase the time of isolation and thus mitochondria exposure to protease, although 
Buffer A contains 0.5% BSA. (30-60 sec) 
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6. Pour the homogenate into two (2) pre-cooled 50 mL centrifuge tubes and centrifuge 
3 minutes x 1500g. 
7. Decant the supernatant into two, clean, pre-chilled 50 mL centrifuge tubes and 
centrifuge 5 minutes x 10,000g. 
8. Discard the supernatants and resuspend each of the pellets in --0.5 mL of Buffer B 
using a pipetor to gently "wash" the pellets into homogeneous suspension. Combine 
all suspensions into one (l) 50 mL centrifuge tube, fill with Buffer B, and centrifuge 3 
minutes x 2300g. 
9. Carefully decant the supernatant (containing the mitochondrial fraction) into a 
clean, pre-chilled 50 mL centrifuge hlbe. Discard the "fluffy" pellet that results from 
this low-speed spin. 
10. Centrifuge the supernatant for 5 minutes x 10,000 g. 
11. Pour off (discard) the supernatant, and resuspend the pellet in --150 to 200 J!L of 
Buffer B (see Step 8, above). 
12. Alternatively, the centrifugation times can be cut to 3-5-3-5 min, respectively 
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